TAO Synergies Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • TAOX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.53
  • (As of Friday Closing)

TAO Synergies General Information

Description

TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.

Contact Information

Formerly Known As
Neurotrope Bioscience, Neurotrope Bioscience, Inc., Synaptogenix
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 1185 Avenue of the Americas
  • 3rd Floor
  • New York, NY 10036
  • United States
+1 (800)
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Corporate Office
  • 1185 Avenue of the Americas
  • 3rd Floor
  • New York, NY 10036
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TAO Synergies Stock Performance

As of 20-Nov-2026, TAO Synergies’s stock price is $1.53. Its current market cap is $12.5M with 8.04M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.53 $1.73 $1.50 - $7.85 $12.5M 8.04M 178K $0.29

TAO Synergies Financials Summary

As of 30-Sep-2026, TAO Synergies has a trailing 12-month revenue of $815K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 36,075 25,393 (17,051) (24,495)
Revenue 815 299 0 0
EBITDA (6,403) (29,177) (14,039) (7,681)
Net Income (6,269) (28,737) (12,769) (6,039)
Total Assets 28,328 25,835 17,734 31,114
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TAO Synergies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TAO Synergies‘s full profile, request access.

Request a free trial

TAO Synergies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the
Pharmaceuticals
New York, NY
4 As of 2025

Rockville, MD
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TAO Synergies Competitors (3)

One of TAO Synergies’s 3 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
Arrowhead Pharmaceuticals Corporation Pasadena, CA
You’re viewing 3 of 3 competitors. Get the full list »

TAO Synergies Patents

TAO Synergies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240408056-A1 Methods for repairing nerve damage using pkc activating therapeutic agents Pending 12-Jun-2023
WO-2024258981-A2 Methods for repairing nerve damage using pkc activating therapeutic agents Inactive 12-Jun-2023
WO-2024258981-A3 Methods for repairing nerve damage using pkc activating therapeutic agents Inactive 12-Jun-2023
WO-2024019953-A1 Method of enhancing recovery from long covid Inactive 18-Jul-2022
EP-4362964-A1 Method of inducing synaptogenesis by administering angiotensin and analogues thereof Inactive 29-Jun-2021 A61P25/28
To view TAO Synergies’s complete patent history, request access »

TAO Synergies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TAO Synergies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore TAO Synergies‘s full profile, request access.

Request a free trial

TAO Synergies Investments (2)

TAO Synergies’s most recent deal was a Early Stage VC with PsygaBio. The deal was made on 09-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PsygaBio 09-Apr-2024 Early Stage VC Drug Discovery
Cannasoul Analytics 02-Nov-2023 Later Stage VC Drug Discovery
To view TAO Synergies’s complete investments history, request access »

TAO Synergies ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.04 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Software & Services

Industry

of 899

Rank

Percentile

Data Processing

Subindustry

of 98

Rank

Percentile

To view TAO Synergies’s complete esg history, request access »

TAO Synergies Exits (1)

TAO Synergies’s most recent exit was on 09-Apr-2024 from PsygaBio. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
PsygaBio 09-Apr-2024 Completed
To view TAO Synergies’s complete exits history, request access »

TAO Synergies FAQs

  • When was TAO Synergies founded?

    TAO Synergies was founded in 2012.

  • Where is TAO Synergies headquartered?

    TAO Synergies is headquartered in New York, NY.

  • What is the size of TAO Synergies?

    TAO Synergies has 4 total employees.

  • What industry is TAO Synergies in?

    TAO Synergies’s primary industry is Pharmaceuticals.

  • Is TAO Synergies a private or public company?

    TAO Synergies is a Public company.

  • What is TAO Synergies’s stock symbol?

    The ticker symbol for TAO Synergies is TAOX.

  • What is the current stock price of TAO Synergies?

    As of 20-Nov-2026 the stock price of TAO Synergies is $1.53.

  • What is the current market cap of TAO Synergies?

    The current market capitalization of TAO Synergies is $12.5M.

  • What is TAO Synergies’s current revenue?

    The trailing twelve month revenue for TAO Synergies is $815K.

  • Who are TAO Synergies’s competitors?

    Regenxbio, ACADIA Pharmaceuticals, and Arrowhead Pharmaceuticals are competitors of TAO Synergies.

  • What is TAO Synergies’s annual earnings per share (EPS)?

    TAO Synergies’s EPS for 12 months was $0.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process